Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 449 entries
Sorted by: Best Match Show Resources per page
Brentuximab Vedotin Infusion Reaction Management: A Case Study.

Journal of the advanced practitioner in oncology

Comer H, Cardwell K.
PMID: 30310723
J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 01.

We report a case of a grade 3 (Common Terminology Criteria for Adverse Events [CTCAE]) infusion reaction to brentuximab vedotin (Adcetris), in a patient with refractory Hodgkin lymphoma, at a large National Cancer Institute-designated cancer center in the Midwest...

Cite
Comer H, Cardwell K. Brentuximab Vedotin Infusion Reaction Management: A Case Study. J Adv Pract Oncol. 2017;8(6):626-629
Comer, H., & Cardwell, K. (2017). Brentuximab Vedotin Infusion Reaction Management: A Case Study. Journal of the advanced practitioner in oncology, 8(6), 626-629.
Comer, Holly, and Cardwell, Kimbra. "Brentuximab Vedotin Infusion Reaction Management: A Case Study." Journal of the advanced practitioner in oncology vol. 8,6 (2017): 626-629.
Comer H, Cardwell K. Brentuximab Vedotin Infusion Reaction Management: A Case Study. J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 01. PMID: 30310723; PMCID: PMC6167082.
Copy Download .nbib Format: NLM
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.

Contemporary clinical trials communications

Pfister C, Harter V, Allory Y, Radvanyi F, Culine S.
PMID: 32083220
Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar.

The main objective of the French GETUG/AFU V05 VESPER randomized phase III study was to assess the efficacy of dd-MVAC and GC in term of progression-free survival in patients for whom chemotherapy has been decided, before or after surgery....

Cite
Pfister C, Harter V, Allory Y, et al. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Contemp Clin Trials Commun. 2020;17:100536doi: 10.1016/j.conctc.2020.100536.
Pfister, C., Harter, V., Allory, Y., Radvanyi, F., Culine, S. (2020). Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Contemporary clinical trials communications, 17100536. https://doi.org/10.1016/j.conctc.2020.100536
Pfister, Christian, et al. "Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial." Contemporary clinical trials communications vol. 17 (2020): 100536. doi: https://doi.org/10.1016/j.conctc.2020.100536
Pfister C, Harter V, Allory Y, Radvanyi F, Culine S. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Contemp Clin Trials Commun. 2020 Jan 30;17:100536. doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar. PMID: 32083220; PMCID: PMC7025084.
Copy Download .nbib Format: NLM
Primary Oro-Facial Manifestations of Langerhans Cell Histiocytosis in Pediatric Age: A Bi-Institutional Retrospective Study on 45 Cases.

Children (Basel, Switzerland)

Capodiferro S, Tempesta A, Limongelli L, Ingravallo G, Maiorano E, Sfasciotti GL, Bossù M, Polimeni A, Favia G.
PMID: 32825016
Children (Basel). 2020 Aug 19;7(9). doi: 10.3390/children7090104.

AIMS: Langerhans Cell Histiocytosis is a rare hematologic disorder usually affecting children and most commonly involving the head and neck region. Primary oro-facial manifestations are rare, and their diagnosis is often challenging as they are numerous and often resemble...

Cite
Capodiferro S, Tempesta A, Limongelli L, et al. Primary Oro-Facial Manifestations of Langerhans Cell Histiocytosis in Pediatric Age: A Bi-Institutional Retrospective Study on 45 Cases. Children (Basel). 2020;7(9)doi: 10.3390/children7090104.
Capodiferro, S., Tempesta, A., Limongelli, L., Ingravallo, G., Maiorano, E., Sfasciotti, G. L., Bossù, M., Polimeni, A., & Favia, G. (2020). Primary Oro-Facial Manifestations of Langerhans Cell Histiocytosis in Pediatric Age: A Bi-Institutional Retrospective Study on 45 Cases. Children (Basel, Switzerland), 7(9), . https://doi.org/10.3390/children7090104
Capodiferro, Saverio, et al. "Primary Oro-Facial Manifestations of Langerhans Cell Histiocytosis in Pediatric Age: A Bi-Institutional Retrospective Study on 45 Cases." Children (Basel, Switzerland) vol. 7,9 (2020). doi: https://doi.org/10.3390/children7090104
Capodiferro S, Tempesta A, Limongelli L, Ingravallo G, Maiorano E, Sfasciotti GL, Bossù M, Polimeni A, Favia G. Primary Oro-Facial Manifestations of Langerhans Cell Histiocytosis in Pediatric Age: A Bi-Institutional Retrospective Study on 45 Cases. Children (Basel). 2020 Aug 19;7(9). doi: 10.3390/children7090104. PMID: 32825016; PMCID: PMC7552718.
Copy Download .nbib Format: NLM
Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.

Seminars in radiation oncology

Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M.
PMID: 10717177
Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185.

Recommendations for the treatment of "poor prognosis" stages I and II Hodgkin's disease (HD) depend on the extent of staging. For centers that favor exploratory laparotomy and splenectomy, the standard treatment after negative surgical staging remains subtotal lymphoid irradiation....

Cite
Cosset JM, Fermé C, Noordijk EM, et al. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996;6(3):185-195doi: 10.1053/SRAO00600185.
Cosset, J. M., Fermé, C., Noordijk, E. M., Dubray, B. M., Thirion, P., & Henry-Amar, M. (1996). Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Seminars in radiation oncology, 6(3), 185-195. https://doi.org/10.1053/SRAO00600185
Cosset, et al. "Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease." Seminars in radiation oncology vol. 6,3 (1996): 185-195. doi: https://doi.org/10.1053/SRAO00600185
Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185. PMID: 10717177.
Copy Download .nbib Format: NLM
Gliomas in children.

Current treatment options in neurology

Minturn JE, Fisher MJ.
PMID: 23440592
Curr Treat Options Neurol. 2013 Jun;15(3):316-27. doi: 10.1007/s11940-013-0225-x.

OPINION STATEMENT: Gliomas are the most common brain tumor in children and represent nearly 50 % of all pediatric central nervous system (CNS) tumors. They are a heterogeneous group of diseases, ranging from highly malignant and frequently fatal to...

Cite
Minturn JE, Fisher MJ. Gliomas in children. Curr Treat Options Neurol. 2013;15(3):316-27doi: 10.1007/s11940-013-0225-x.
Minturn, J. E., & Fisher, M. J. (2013). Gliomas in children. Current treatment options in neurology, 15(3), 316-27. https://doi.org/10.1007/s11940-013-0225-x
Minturn, Jane E, and Fisher, Michael J. "Gliomas in children." Current treatment options in neurology vol. 15,3 (2013): 316-27. doi: https://doi.org/10.1007/s11940-013-0225-x
Minturn JE, Fisher MJ. Gliomas in children. Curr Treat Options Neurol. 2013 Jun;15(3):316-27. doi: 10.1007/s11940-013-0225-x. PMID: 23440592.
Copy Download .nbib Format: NLM
Pregnancy in a patient with cancer and heart failure: challenges and complexities.

Journal of the advanced practitioner in oncology

Fadol AP, Lech T, Bickford C, Yusuf SW.
PMID: 25031933
J Adv Pract Oncol. 2012 Mar;3(2):85-93. doi: 10.6004/jadpro.2012.3.2.3.

A 24-year-old African American female (L.R.) with a history of smoking and gestational diabetes was diagnosed with Hodgkin lymphoma. She received multiple chemotherapies, including six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), followed by radiation therapy to left...

Cite
Fadol AP, Lech T, Bickford C, et al. Pregnancy in a patient with cancer and heart failure: challenges and complexities. J Adv Pract Oncol. 2012;3(2):85-93doi: 10.6004/jadpro.2012.3.2.3.
Fadol, A. P., Lech, T., Bickford, C., & Yusuf, S. W. (2012). Pregnancy in a patient with cancer and heart failure: challenges and complexities. Journal of the advanced practitioner in oncology, 3(2), 85-93. https://doi.org/10.6004/jadpro.2012.3.2.3
Fadol, Anecita P, et al. "Pregnancy in a patient with cancer and heart failure: challenges and complexities." Journal of the advanced practitioner in oncology vol. 3,2 (2012): 85-93. doi: https://doi.org/10.6004/jadpro.2012.3.2.3
Fadol AP, Lech T, Bickford C, Yusuf SW. Pregnancy in a patient with cancer and heart failure: challenges and complexities. J Adv Pract Oncol. 2012 Mar;3(2):85-93. doi: 10.6004/jadpro.2012.3.2.3. PMID: 25031933; PMCID: PMC4093307.
Copy Download .nbib Format: NLM
The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy.

Journal of blood medicine

Bayoumi Y, Al-Homaidi A, Zaidi S, Tailor I, Motiabi I, Alshehri N, Al-Ghazali A, Almudaibigh S.
PMID: 25848329
J Blood Med. 2015 Mar 20;6:87-92. doi: 10.2147/JBM.S69267. eCollection 2015.

BACKGROUND/PURPOSE: The aim of this study was to evaluate the role of consolidation radiotherapy (RT) in advanced-stage Hodgkin's disease (HD) with initial bulky sites after radiological complete remission (CR) or partial response (PR) with positron emission tomography-negative (metabolic CR)...

Cite
Bayoumi Y, Al-Homaidi A, Zaidi S, et al. The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. J Blood Med. 2015;6:87-92doi: 10.2147/JBM.S69267.
Bayoumi, Y., Al-Homaidi, A., Zaidi, S., Tailor, I., Motiabi, I., Alshehri, N., Al-Ghazali, A., & Almudaibigh, S. (2015). The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. Journal of blood medicine, 687-92. https://doi.org/10.2147/JBM.S69267
Bayoumi, Yasser, et al. "The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy." Journal of blood medicine vol. 6 (2015): 87-92. doi: https://doi.org/10.2147/JBM.S69267
Bayoumi Y, Al-Homaidi A, Zaidi S, Tailor I, Motiabi I, Alshehri N, Al-Ghazali A, Almudaibigh S. The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. J Blood Med. 2015 Mar 20;6:87-92. doi: 10.2147/JBM.S69267. eCollection 2015. PMID: 25848329; PMCID: PMC4374789.
Copy Download .nbib Format: NLM
A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.

Frontiers in immunology

Liu Z, Tang Q, Qi T, Othmane B, Yang Z, Chen J, Hu J, Zu X.
PMID: 34484235
Front Immunol. 2021 Aug 13;12:725223. doi: 10.3389/fimmu.2021.725223. eCollection 2021.

BACKGROUND: Bladder cancer (BLCA) is one of the most common urinary malignancies with poor prognosis. There is an unmet need to develop novel robust tools to predict prognosis and treatment efficacy for BLCA.METHODS: The hypoxia-related genes were collected from...

Cite
Liu Z, Tang Q, Qi T, et al. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. Front Immunol. 2021;12:725223doi: 10.3389/fimmu.2021.725223.
Liu, Z., Tang, Q., Qi, T., Othmane, B., Yang, Z., Chen, J., Hu, J., & Zu, X. (2021). A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. Frontiers in immunology, 12725223. https://doi.org/10.3389/fimmu.2021.725223
Liu, Zhi, et al. "A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer." Frontiers in immunology vol. 12 (2021): 725223. doi: https://doi.org/10.3389/fimmu.2021.725223
Liu Z, Tang Q, Qi T, Othmane B, Yang Z, Chen J, Hu J, Zu X. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer. Front Immunol. 2021 Aug 13;12:725223. doi: 10.3389/fimmu.2021.725223. eCollection 2021. PMID: 34484235; PMCID: PMC8415032.
Copy Download .nbib Format: NLM
In vitro Cytotoxic Activities and Molecular Mechanisms of Angelica shikokiana Extract and its Isolated Compounds.

Pharmacognosy magazine

Mira A, Shimizu K.
PMID: 27013795
Pharmacogn Mag. 2015 Oct;11:S564-9. doi: 10.4103/0973-1296.172962.

BACKGROUND: Angelica shikokiana is a Japanese medicinal herb that is included among food and drug preparations protecting against cancer; however, there is no previous report about the cytotoxicity of A. shikokiana or its bioactive compounds.OBJECTIVE: This study was designed...

Cite
Mira A, Shimizu K. In vitro Cytotoxic Activities and Molecular Mechanisms of Angelica shikokiana Extract and its Isolated Compounds. Pharmacogn Mag. 2015;11:S564-9doi: 10.4103/0973-1296.172962.
Mira, A., & Shimizu, K. (2015). In vitro Cytotoxic Activities and Molecular Mechanisms of Angelica shikokiana Extract and its Isolated Compounds. Pharmacognosy magazine, 11S564-9. https://doi.org/10.4103/0973-1296.172962
Mira, Amira, and Shimizu, Kuniyoshi. "In vitro Cytotoxic Activities and Molecular Mechanisms of Angelica shikokiana Extract and its Isolated Compounds." Pharmacognosy magazine vol. 11 (2015): S564-9. doi: https://doi.org/10.4103/0973-1296.172962
Mira A, Shimizu K. In vitro Cytotoxic Activities and Molecular Mechanisms of Angelica shikokiana Extract and its Isolated Compounds. Pharmacogn Mag. 2015 Oct;11:S564-9. doi: 10.4103/0973-1296.172962. PMID: 27013795; PMCID: PMC4787089.
Copy Download .nbib Format: NLM
Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature.

Journal of the International AIDS Society

Sculier D, Doco-Lecompte T, Rougemont M, Calmy A.
PMID: 25394154
J Int AIDS Soc. 2014 Nov 02;17(4):19650. doi: 10.7448/IAS.17.4.19650. eCollection 2014.

INTRODUCTION: In HIV patients, haemophagocytic syndrome (HPS) may occur in the presence of cancer, concomitant viral infection, HIV primo-infection or at the initiation of highly active antiretroviral therapy (HAART). Hodgkin lymphoma remains a rare cause of HPS. We describe...

Cite
Sculier D, Doco-Lecompte T, Rougemont M, et al. Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature. J Int AIDS Soc. 2014;17(4):19650doi: 10.7448/IAS.17.4.19650.
Sculier, D., Doco-Lecompte, T., Rougemont, M., & Calmy, A. (2014). Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature. Journal of the International AIDS Society, 17(4), 19650. https://doi.org/10.7448/IAS.17.4.19650
Sculier, Delphine, et al. "Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature." Journal of the International AIDS Society vol. 17,4 (2014): 19650. doi: https://doi.org/10.7448/IAS.17.4.19650
Sculier D, Doco-Lecompte T, Rougemont M, Calmy A. Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature. J Int AIDS Soc. 2014 Nov 02;17(4):19650. doi: 10.7448/IAS.17.4.19650. eCollection 2014. PMID: 25394154; PMCID: PMC4224866.
Copy Download .nbib Format: NLM
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.

International journal of radiation oncology, biology, physics

Baues C, Goergen H, Fuchs M, Rosenbrock J, Celik E, Eich H, Kobe C, Voltin CA, Engert A, Borchmann P, Marnitz S.
PMID: 34389407
Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):900-906. doi: 10.1016/j.ijrobp.2021.07.1697. Epub 2021 Aug 11.

PURPOSE: The HD16 trial of the German Hodgkin Study Group (NCT00736320) demonstrated that radiation therapy in early-stage Hodgkin lymphoma without risk factors cannot be safely omitted, and therefore combined modality therapy (CMT) remains the standard treatment. To demonstrate the...

Cite
Baues C, Goergen H, Fuchs M, et al. Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial. Int J Radiat Oncol Biol Phys. 2021;111(4):900-906doi: 10.1016/j.ijrobp.2021.07.1697.
Baues, C., Goergen, H., Fuchs, M., Rosenbrock, J., Celik, E., Eich, H., Kobe, C., Voltin, C. A., Engert, A., Borchmann, P., & Marnitz, S. (2021). Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial. International journal of radiation oncology, biology, physics, 111(4), 900-906. https://doi.org/10.1016/j.ijrobp.2021.07.1697
Baues, Christian, et al. "Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial." International journal of radiation oncology, biology, physics vol. 111,4 (2021): 900-906. doi: https://doi.org/10.1016/j.ijrobp.2021.07.1697
Baues C, Goergen H, Fuchs M, Rosenbrock J, Celik E, Eich H, Kobe C, Voltin CA, Engert A, Borchmann P, Marnitz S. Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial. Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):900-906. doi: 10.1016/j.ijrobp.2021.07.1697. Epub 2021 Aug 11. PMID: 34389407.
Copy Download .nbib Format: NLM
MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines.

Prostate cancer and prostatic diseases

Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST, Parkin JD.
PMID: 12497102
Prostate Cancer Prostatic Dis. 2000 Aug;3(2):66-75. doi: 10.1038/sj.pcan.4500394.

Multidrug resistant prostate cancer cell lines DU 0.03 and PC 0.03 were established from the parental prostate cancer cell lines DU145 and PC-3 respectively by stepwise selection in doxorubicin (DOX) from 0.001 to 0.03 &mgr;g/ml. As cells adapted to...

Cite
Zalcberg J, Hu XF, Slater A, et al. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis. 2000;3(2):66-75doi: 10.1038/sj.pcan.4500394.
Zalcberg, J., Hu, X. F., Slater, A., Parisot, J., El-Osta, S., Kantharidis, P., Chou, S. T., & Parkin, J. D. (2000). MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate cancer and prostatic diseases, 3(2), 66-75. https://doi.org/10.1038/sj.pcan.4500394
Zalcberg, J, et al. "MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines." Prostate cancer and prostatic diseases vol. 3,2 (2000): 66-75. doi: https://doi.org/10.1038/sj.pcan.4500394
Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST, Parkin JD. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis. 2000 Aug;3(2):66-75. doi: 10.1038/sj.pcan.4500394. PMID: 12497102.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 449 entries